- patients with psoriasis or other exfoliative disease, porphyria, epilepsy, myasthenia gravis, advanced liver failure or glucose-6-phosphate dehydrogenase deficiency. - alt / ast> 5 times the upper limit of normal. - severe chronic kidney disease in stage 4 or requiring dialysis (ie, egfr <30). - pregnancy or breastfeeding. - early transfer to another hospital that is not a study site within 72 hours. - severe heart disease and / or a history of cardiac arrhythmia. - allergy to chloroquine and / or hydroxychloroquine.

- patients with psoriasis or other exfoliative disease, porphyria, epilepsy, myasthenia gravis, advanced liver failure or glucose-6-phosphate dehydrogenase deficiency. - alt / ast> 5 times the upper limit of normal. - severe chronic kidney disease in stage 4 or requiring dialysis (ie, egfr <30). - pregnancy or breastfeeding. - early transfer to another hospital that is not a study site within 72 hours. - severe heart disease and / or a history of cardiac arrhythmia. - allergy to chloroquine and / or hydroxychloroquine.